Polyplus-transfection

The licensing deal grants Roche Glycart access to polyethylenimine for in vitro transfection applications for research purposes.

The company said it will use the funds to advance new siRNA delivery compounds and add 10 new researchers and lab technicians.

The company plans to use the funding to enhance its R&D resources and to hire new researchers and lab technicians.

Metabion will develop custom research reagents and in vitro diagnostics based on Polyplus' ZNA oligonucleotides, which are modified to have increased affinity for nucleic acids while retaining specificity.

The German firm will offer Polyplus-transfection's new ZNA technology, which it said increases the affinity for nucleic acids.

In a new paper, Polyplus-transfection scientists showed that the company's zipped nucleic acids work as hydrolysis probes in quantitative PCR, adding to previous work that demonstrated their use as primers.

The company said the money will primarily be used to support its RNAplus program, which is focused on developing RNAi oligos that do not require delivery reagents.

The firm plans to use the funding to develop oligonucleotide technologies and to add management for the US market.

Sigma-Aldrich will manufacture and sell the French company's oligonucleotides worldwide.

NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.

Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.

A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.

In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.